Funds holding Autolus Therapeutics PLC
ISIN US05280R1005 · United Kingdom · LEI 549300C0KZP8EYROLL02
- Fund holders
- 7
- Of which ETFs
- 5 2 other funds
- Value held
- 2.8M $
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| iShares Biotechnology ETF iShares Trust | 1,428,929 | 2.3M $ | 0.03 % | as of Jun 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 120,878 | 226K $ | 0.00 % | as of May 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 84,409 | 135.1K $ | 0.02 % | as of Jun 30, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 44,936 | 84K $ | 0.44 % | as of May 31, 2026 ↗ |
| ActivePassive International Equity ETF Trust for Professional Managers | 22,753 | 42.5K $ | 0.00 % | as of May 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 10,575 | 19.8K $ | 0.03 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 7,414 | 13.9K $ | 0.02 % | as of May 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 0.44 % | as of May 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 0.03 % | as of May 31, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 0.03 % | as of Jun 30, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 0.02 % | as of May 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 0.02 % | as of Jun 30, 2026 ↗ |
| ActivePassive International Equity ETF Trust for Professional Managers | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 7 | -1 | 1,719,894 | -26.2 % |
| 2026Q2 | 8 | -2 | 2,328,962 | -7.3 % |
| 2026Q1 | 10 | -4 | 2,512,312 | -6.6 % |
| 2025Q4 | 14 | -6 | 2,690,592 | -90.2 % |
| 2025Q3 | 20 | -7 | 27,594,596 | -5.0 % |
| 2025Q2 | 27 | -8 | 29,048,739 | -22.4 % |
| 2025Q1 | 35 | -5 | 37,433,055 | -6.5 % |
| 2024Q4 | 40 | -6 | 40,018,218 | -2.7 % |
| 2024Q3 | 46 | -2 | 41,111,232 | +82.2 % |
| 2024Q2 | 48 | +31 | 22,568,973 | +645.6 % |
| 2024Q1 | 17 | +7 | 3,027,068 | +107.6 % |
| 2023Q4 | 10 | 1,458,187 |
Institutional managers
84 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| MAK CAPITAL ONE LLC | 33,621,487 | 46.4M $ | as of Mar 31, 2026 |
| Blackstone Inc. | 20,485,611 | 28.3M $ | as of Mar 31, 2026 |
| Syncona Portfolio Ltd | 16,640,720 | 23M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 15,800,000 | 21.8M $ | as of Mar 31, 2026 |
| Tetragon Partners GP Ltd | 9,500,000 | 13.1M $ | as of Mar 31, 2026 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 9,489,345 | 12.1M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 4,447,910 | 6.1M $ | as of Mar 31, 2026 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | 4.6M $ | as of Mar 31, 2026 |
| Laurion Capital Management LP | 3,316,626 | 4.6M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 2,299,499 | 3.2M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,844,671 | 2.5M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 1,480,732 | 2M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,305,779 | 1.8M $ | as of Mar 31, 2026 |
| Cetera Investment Advisers | 1,129,074 | 1.6M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 971,691 | 1.3M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 941,823 | 1.3M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 935,403 | 1.2M $ | as of Mar 31, 2026 |
| Alphabet Inc. | 698,262 | 963.6K $ | as of Mar 31, 2026 |
| Marex Group plc | 542,857 | 749.1K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 459,404 | 634K $ | as of Mar 31, 2026 |
| Hennion & Walsh Asset Management, Inc. | 440,206 | 607.5K $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 426,983 | 589.2K $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 399,143 | 550.8K $ | as of Mar 31, 2026 |
| Privium Fund Management B.V. | 363,430 | 501.5K $ | as of Mar 31, 2026 |
| EDENTREE ASSET MANAGEMENT Ltd | 300,000 | 414K $ | as of Mar 31, 2026 |
Declared shareholders of Autolus Therapeutics PLC
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Armistice Capital, LLC and 1 other | 5.64 % | 15,000,000 | as of Jun 30, 2026 · SCHEDULE 13G |
| Renata Kellnerova and 3 others | 5.60 % | 14,782,275 | as of Aug 27, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Funds holding Autolus Therapeutics PLC". https://titelia.com/en/stocks/autolus-therapeutics-plc-US05280R1005